KRAS and non-small cell lung carcinoma: KO-2806 has been shown to improve efficacy of KRASG12C inhibitor adagrasib by blocking compensatory bypass mechanisms of KRAS inhibition in KRAS-mutant non-small cell lung cancer (NSCLC).12